Open AccessIbrutinib and rituximab induced rapid response in refractory Richter syndrome
Author(s) -
Lamar Zanetta,
Kennedy LeAnne,
Kennedy Brooke,
Lynch Mary,
Goad Amanda,
Hurd David,
McIver Zachariah
Publication year - 2015
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.269
Subject(s) - ibrutinib , medicine , rituximab , refractory (planetary science) , complete response , oncology , lymphoma , leukemia , chemotherapy , chronic lymphocytic leukemia , physics , astrobiology
Key Clinical Message We report a 53‐year‐old man diagnosed with Richter syndrome. He was heavily pretreated and was refractory to prior therapy. He received rituximab and ibrutinib, and achieved a significant response after 1 month of therapy. Our case illustrates the importance of investigation of rituximab and ibrutinib in Richter's syndrome.